drugset / Trial / NCT06526819
SMP-3124LP in Adults With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
Timeline
- Start
- 2024-08-14
- Primary completion
- 2028-12
- Completion
- 2029-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SMP-3124 | Unknown | 20 mg/m2 | Intravenous |
| Subject | SMP-3124 | Unknown | 40 mg/m2 | Intravenous |
| Subject | SMP-3124 | Unknown | 60 mg/m2 | Intravenous |
| Subject | SMP-3124 | Unknown | 90 mg/m2 | Intravenous |
| Subject | SMP-3124 | Unknown | 120 mg/m2 | Intravenous |